Breaking News Instant updates and real-time market news.

ALNY

Alnylam

$88.16

0.97 (1.11%)

07:04
10/04/18
10/04
07:04
10/04/18
07:04

Alnylam reports updated 'positive' results from Phase 1/2 study of lumasiran

Alnylam Pharmaceuticals announced updated positive results from its Phase 1/2 clinical study of lumasiran, an investigational, subcutaneously administered RNAi therapeutic targeting glycolate oxidase for the treatment of primary hyperoxaluria type 1. The company also announced the initiation of ILLUMINATE-A, a global Phase 3 pivotal trial of lumasiran in children and adults with PH1. The study will enroll approximately 30 patients and is designed in alignment with FDA with a primary endpoint based on reduction of urinary oxalate at six months. Alnylam expects to report topline results from ILLUMINATE-A in late 2019 and, if positive, submit filings for regulatory approval starting in early 2020. New results from the Phase 1/2 study were as of a data cut-off date of August 15, 2018. Lumasiran demonstrated a mean maximal reduction in urinary oxalate of 75 percent relative to baseline across cohorts dosed at 1 mg/kg monthly or 3 mg/kg monthly or quarterly. The mean reduction relative to baseline was 66 percent when measured 28 days post last dose. All patients achieved oxalate lowering to less than 1.5 times the upper limit of normal. Among patients receiving 3 mg/kg monthly or quarterly doses of lumasiran, 83 percent achieved urinary oxalate levels within the normal range. Furthermore, lumasiran-treated patients in all cohorts experienced a mean maximal decrease of 76 percent in the ratio of urinary oxalate to creatinine - a corroborative measure of oxalate reduction that addresses the variability that is inherent to 24 hour urine collections. The Phase 1/2 safety results in patients with PH1 were based on a median study duration of seven months since first dose. As of the data cut-off date, there were no discontinuations from study treatment. Serious adverse events were reported for one patient receiving placebo and five patients receiving lumasiran; none were related to study drug. The placebo patient experienced acute pyelonephritis and kidney stones. The lumasiran patients with SAEs included one patient with vomiting, one patient with abdominal pain, fever and vomiting, one patient with gastroenteritis, and two patients with kidney stones. Adverse events were reported in three patients during placebo dosing and 19 patients after lumasiran dosing. The majority of AEs were mild or moderate in severity and were assessed as unrelated to study drug. Injection site reactions were reported in three patients receiving lumasiran. ISRs were mild or moderate in severity and were self-limiting. Lumasiran was not associated with any clinically significant adverse laboratory findings. In patients receiving lumasiran, plasma glycolate levels increased consistent with the pharmacology of lumasiran and results from healthy volunteers in Part A of the Phase 1/2 study. This increase was not associated with any safety findings.

  • 27

    Nov

ALNY Alnylam
$88.16

0.97 (1.11%)

10/01/18
CANT
10/01/18
INITIATION
Target $135
CANT
Overweight
Alnylam initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Alethia Young started Alnylam Pharmaceuticals with an Overweight rating and $135 price target.
09/28/18
PIPR
09/28/18
NO CHANGE
Target $160
PIPR
Overweight
Piper says Alnylam making transition to commercial play on orphan diseases
After Alnylam announced an NDA filing on Onpattro for hATTR Amyloidosis in Japan, Piper Jaffray analyst Edward Tenthoff said the company is transitioning toward being a commercial play on orphan diseases. The analyst, who forecasts 2018 Onpattro sales of $10.7M growing to $81M in 2019, keeps an Overweight and $160 price target on Alnylam shares.
09/27/18
PIPR
09/27/18
NO CHANGE
Target $160
PIPR
Overweight
Alnylam weakness on safety concerns a buying opportunity, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff attributes the initial weakness today in shares of Alnylam Pharmaceuticals to safety concerns from the interim Phase III givosiran data in acute hepatic porphyrias. Safety was consistent with prior Phase I data showing no additional deaths or cases of pancreatitis, five serious adverse events were due to underlying disease and one discontinuation for liver transaminase elevation resolved, Tenthoff tells investors in a research note. The analyst says he's a buyer of Alnylam due to the unmet medical need in acute hepatic porphyrias. Tenthoff reiterates an Overweight rating on Alnylam with a $160 price target. The stock is down 1%, or $1.12, to $90.21 in early trading.
09/24/18
PIPR
09/24/18
NO CHANGE
Target $50
PIPR
Neutral
Ionis platelet issue now appears removed, says Piper Jaffray
The most important takeaway from Ionis Pharmaceuticals' APO(a)-LRx results this morning is that there appears to be no platelet issue associated with the LICA technology, Piper Jaffray analyst Tyler Van Buren tells investors in a research note titled "These LICA Results Are A Big Deal - Platelet Issue Now Appears Removed." As it relates to Tegsedi specifically, the analyst says that while the product's subcutaneous dosing provides a clear competitive advantage to Alnylam's (ALNY) Onpattro infusion regimen, many view it as being offset by the need for bi-weekly platelet monitoring. However, Van Buren now believes that the need for platelet monitoring is definitively removed with Ionis' LICA technology. He believes this morning's results provide significant long-term validation for Ionis' LICA technology platform. The analyst keeps a Neutral rating on Ionis Pharmaceuticals with a $50 price target.

TODAY'S FREE FLY STORIES

DB

Deutsche Bank

$6.98

-0.19 (-2.65%)

, COF

Capital One

$83.06

-2.68 (-3.13%)

17:57
08/23/19
08/23
17:57
08/23/19
17:57
Periodicals
Deutsche Bank, Capital One won't say if they have Trump's tax returns, NYP says »

Deutsche Bank (DB) and…

DB

Deutsche Bank

$6.98

-0.19 (-2.65%)

COF

Capital One

$83.06

-2.68 (-3.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

MXIM

Maxim Integrated

$52.14

-2.42 (-4.44%)

17:53
08/23/19
08/23
17:53
08/23/19
17:53
Hot Stocks
Maxim Integrated's Jain sells 12,683 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

GLD

SPDR Gold Shares

$144.15

2.77 (1.96%)

17:42
08/23/19
08/23
17:42
08/23/19
17:42
Hot Stocks
SPDR Gold Shares holdings rise to 859.83MT to 854.84MT »

This is the fourth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AUMN

Golden Minerals

$0.27

0.0159 (6.38%)

17:33
08/23/19
08/23
17:33
08/23/19
17:33
Hot Stocks
Golden Minerals receives noncompliance notice from NYSE »

Golden Minerals announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DMPI

DelMar Pharmaceuticals

$0.77

0.0047 (0.61%)

17:25
08/23/19
08/23
17:25
08/23/19
17:25
Hot Stocks
Intracoastal Capital reports 9.99% passive stake in DelMar Pharmaceuticals »

Intracoastal Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RTN

Raytheon

$180.58

-6.44 (-3.44%)

17:22
08/23/19
08/23
17:22
08/23/19
17:22
Hot Stocks
Raytheon awarded $534M Army contract »

Raytheon was awarded a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UHAL

Amerco

$339.43

-2.97 (-0.87%)

17:21
08/23/19
08/23
17:21
08/23/19
17:21
Hot Stocks
Amerco announces special cash dividend of 50c per share »

The dividend will be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTLA

Intellia Therapeutics

$15.77

-1.08 (-6.41%)

17:20
08/23/19
08/23
17:20
08/23/19
17:20
Syndicate
Breaking Syndicate news story on Intellia Therapeutics »

Intellia Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GD

General Dynamics

$183.42

-4.19 (-2.23%)

17:19
08/23/19
08/23
17:19
08/23/19
17:19
Hot Stocks
General Dynamics awarded $1.08B Navy contract modification »

General Dynamics has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVLN

Novelion Therapeutics

$0.66

-0.0523 (-7.37%)

17:17
08/23/19
08/23
17:17
08/23/19
17:17
Hot Stocks
Stonepine Capital reports 6.1% passive stake in Novelion Therapeutics »

Stonepine Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LMT

Lockheed Martin

$376.85

-8.91 (-2.31%)

17:14
08/23/19
08/23
17:14
08/23/19
17:14
Hot Stocks
Lockheed Martin awarded $2.43B Navy contract modification »

Lockheed Martin has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ONCS

OncoSec

$1.84

-0.03 (-1.60%)

17:14
08/23/19
08/23
17:14
08/23/19
17:14
Syndicate
Breaking Syndicate news story on OncoSec »

OncoSec files $50M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TNXP

Tonix Pharmaceuticals

$0.42

-0.0249 (-5.60%)

17:09
08/23/19
08/23
17:09
08/23/19
17:09
Syndicate
Breaking Syndicate news story on Tonix Pharmaceuticals »

Tonix Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$284.86

-7.5 (-2.57%)

17:08
08/23/19
08/23
17:08
08/23/19
17:08
General News
Trump to raises tariff rates on Chinese goods, CNBC says »

U.S. President Donald…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$284.86

-7.5 (-2.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATIS

Attis Industries

$1.03

-0.08 (-7.21%)

17:06
08/23/19
08/23
17:06
08/23/19
17:06
Hot Stocks
Attis Industries provides update on status of Nasdaq listing »

Attis Industries…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVEO

Civeo

$1.32

-0.07 (-5.04%)

17:04
08/23/19
08/23
17:04
08/23/19
17:04
Syndicate
Breaking Syndicate news story on Civeo »

Civeo files $300M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGO

Assured Guaranty

$42.56

-1.09 (-2.50%)

16:58
08/23/19
08/23
16:58
08/23/19
16:58
Hot Stocks
Assured Guaranty CEO sells 30,300 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RMED

Ra Medical Systems

$1.87

-0.055 (-2.86%)

16:50
08/23/19
08/23
16:50
08/23/19
16:50
Hot Stocks
Ra Medical Systems discloses NYSE notice related to 10-Q filing delay »

Ra Medical Systems…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PBA

Pembina Pipeline

$35.73

-0.81 (-2.22%)

16:47
08/23/19
08/23
16:47
08/23/19
16:47
Syndicate
Breaking Syndicate news story on Pembina Pipeline »

Pembina Pipeline files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

APEN

Apollo Endosurgery

$3.50

(0.00%)

16:44
08/23/19
08/23
16:44
08/23/19
16:44
Syndicate
Breaking Syndicate news story on Apollo Endosurgery »

Apollo Endosurgery files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:40
08/23/19
08/23
16:40
08/23/19
16:40
General news
Fed's Clarida said the global economy has worsened »

Fed's Clarida said…

LQDA

Liquidia Technologies

$5.23

-0.38 (-6.77%)

16:35
08/23/19
08/23
16:35
08/23/19
16:35
Syndicate
Breaking Syndicate news story on Liquidia Technologies »

Liquidia Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

V

Visa

$175.24

-4.91 (-2.73%)

16:32
08/23/19
08/23
16:32
08/23/19
16:32
Hot Stocks
Visa CFO Prabhu sells over 25,000 class A common shares »

Visa vice chairman and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

  • 27

    Oct

QCOM

Qualcomm

$73.57

-3.55 (-4.60%)

16:31
08/23/19
08/23
16:31
08/23/19
16:31
Hot Stocks
Qualcomm CFO Dave Wise to retire, Akash Palkhiwala named interim CFO »

Qualcomm announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

  • 06

    Nov

ANFI

Amira Nature Foods

$0.58

-0.0144 (-2.44%)

16:30
08/23/19
08/23
16:30
08/23/19
16:30
Hot Stocks
Amira Nature Foods receives NYSE notice over late Form 20-F filing »

Amira Nature Food…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.